Omnicell (OMCL) is drawing fresh investor attention after its shift toward software and services was underscored by the ANiGENT acquisition, a move that centers on drug diversion detection and recurring revenue potential.

While Omnicell’s latest software-focused move has caught attention, the share price tells a mixed story, with a 90 day share price return of 13.79% contrasting with a 5 year total shareholder return decline of 66.95%, suggesting recent momentum but a still weak long term record.

If Omnicell’s software tilt has you thinking about where healthcare tech could go next, it may be worth scanning 27 healthcare AI stocks as a starting point for other ideas.

With Omnicell now trading at US$41.10 and sitting at a reported 12% intrinsic discount, plus a sizeable gap to analyst targets, you have to ask: is this an overlooked entry point, or is the market already baking in future growth?

Most Popular Narrative: 28.4% Undervalued

Omnicell’s most followed narrative pegs fair value at about $57.43 per share, which sits well above the latest close at $41.10. It leans heavily on the software and cabinet refresh story to bridge that gap.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Curious what sits behind that optimism on software and cabinets. The narrative ties together recurring revenue, margin shifts, and future earnings power in a very specific way. The key is how fast those pieces ramp and what kind of profitability they assume once the refresh cycle kicks in fully.

Result: Fair Value of $57.43 (UNDERVALUED)

However, there are also clear swing factors, including tariff-related cost pressure and any slowdown in cabinet replacements that could challenge the upbeat software-led thesis.

Another Check: Sales Multiple Paints a Different Picture

That 28.4% undervalued fair value hinges on future cash flows, but the current P/S of 1.6x tells a more cautious story. It sits below the US Medical Equipment average of 2.9x, yet above the 1.1x fair ratio, which hints at some valuation risk if sentiment cools or growth underdelivers.

Next Steps

If this mix of opportunity and concern feels finely balanced, it is worth looking at the numbers yourself and forming a view soon. For more detail, see 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Omnicell has you rethinking your watchlist, do not stop here. The real edge comes from regularly refreshing your ideas with fresh, data driven stock lists.

• Target value first and see which companies stand out in our 47 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them.
• Prioritise resilience and check out the 76 resilient stocks with low risk scores for businesses that score well on balance sheet strength and overall risk profile.
• Hunt for future candidates before they are widely followed by scanning the screener containing 24 high quality undiscovered gems and spotting prospects that many investors may be overlooking today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.